Menu
1 min read · estimated
APPROVED USE
What FDA approved
With lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.
LAMPGEN ANALYSIS
Why it matters
EPCORE FL-1 supported a bispecific combination for an earlier relapsed setting than the monotherapy label.
What research teams should watch
Implement the combination-specific step-up calendar and prepare for cytokine release syndrome, neurotoxicity, infection, and cytopenia monitoring.
PRIMARY RECORDS